You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 6, June 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Glucan-Induced Keratoderma in Acquired Immunodeficiency Syndrome

Madeleine Duvic, MD; Mark Reisman; Victoria Finley, MD; Ronald Rapini, MD; Nicholas R. DiLuzio, PhD; Peter W. A. Mansell, MD

Arch Dermatol. 1987;123(6):751-756.


Abstract

• Six of 20 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex receiving intravenous infusions of soluble glucan (β-1-3 polyglucose) developed a keratoderma of the palms and soles. The eruption began during the first two weeks of therapy and resolved two to four weeks after its discontinuation. The eruption was different in appearance from our previously reported keratoderma blennorrhagica in AIDS-associated psoriasis. None of the other 735 patients with AIDS or AIDS-related complex not treated with soluble glucan developed a similar keratoderma. The correlation between receiving glucan and the hyperkeratosis is highly significant. Since glucan is a naturally occurring component of the cell walls of yeast, fungus, and some bacterial organisms, recognition of its ability to induce such a striking reaction pattern may be of general significance and interest, although the reaction itself may be limited to patients with AIDS.

(Arch Dermatol 1987;123:751-756)



Author Affiliations

From the Departments of Dermatology (Drs Duvic, Reisman, Finley, and Rapini) and Internal Medicine (Dr Duvic), the University of Texas Medical School at Houston; the University of Texas Cancer Center, M. D. Anderson Cancer and Tumor Institute and the Institute for Immunologic Disorders, Houston (Drs Duvic and Mansell); and the Department of Physiology, Tulane Medical School, New Orleans (Dr DiLuzio). Dr Reisman is now with the Permanente Medical Group, Redwood City, Calif.


Footnotes

Accepted for publication Dec 30, 1986.

Deceased.

Presented at a poster session of the American Federation of Clinical Research meeting, Washington, DC, May 4, 1986.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.